The molecular mechanisms underlying preconditioning (PC), a powerful endogenous neuroprotective phenomenon, remain to be fully elucidated. Once identified, these endogenous mechanisms could be manipulated for therapeutic gain. We investigated whether lymphocyte cell kinase (Lck), a member of the Src kinases family, mediates PC. We used both in vitro primary cortical neurons and in vivo mouse cerebral focal ischemia models of preconditioning, cellular injury, and neuroprotection. Genetically engineered mice deficient in Lck, gene silencing using siRNA, and pharmacological approaches were used. Cortical neurons preconditioned with sublethal exposure to NMDA or oxygen glucose deprivation (OGD) exhibited enhanced Lck kinase activity, and were resistant to injury on subsequent exposure to lethal levels of NMDA or OGD. Lck gene silencing using siRNA abolished tolerance against both stimuli. Lck Ϫ/Ϫ mice or neurons isolated from Lck Ϫ/Ϫ mice did not exhibit PC-induced tolerance. An Lck antagonist administered to wild-type mice significantly attenuated the neuroprotective effect of PC in the mouse focal ischemia model. Using pharmacological and gene silencing strategies, we also showed that PKC is an upstream regulator of Lck, and Fyn is a downstream target of Lck. We have discovered that Lck plays an essential role in PC in both cellular and animal models of stroke. Our data also show that the PKC-Lck-Fyn axis is a key mediator of PC. These findings provide new opportunities for stroke therapy development.
Introduction
Ischemic tolerance induced by preconditioning (PC) is an endogenous protective mechanism whereby short exposure to sublethal levels of a noxious stimulus results in protection from subsequent more severe levels of exposure to the stimulus (Zemke et al., 2004; Obrenovitch, 2008) . PC occurs in a variety of organs including the heart and brain (Lo et al., 2003) . Numerous preclinical in vitro and in vivo models of PC are available, and clinical data supporting preconditioning in human diseases also exist. For example, transient ischemic attacks (TIAs), caused by brief periods of interruption in blood flow to the brain, are associated with decreased stroke severity and improved outcome (Moncayo et al., 2000; Dirnagl et al., 2009) . To date, all acute neuroprotective stroke therapies have failed in clinical trials, and, consequently, no neuroprotective therapies for acute stroke exist. An alternative strategy to reduce stroke severity may involve enhancing endogenous neuroprotection such as PC (Fisher and Ratan, 2003; Dirnagl et al., 2009) . Although several mediators of PC have been proposed, such as hypoxia-inducible factor, heat shock proteins, erythropoietin, and ion channels (Kennedy and Buchan, 2005; Malhotra et al., 2006; Obrenovitch, 2008; Dirnagl et al., 2009) , the exact mechanisms that mediate preconditioning are not yet fully understood.
Lymphocyte cell kinase (Lck), a member of the Src family kinases, has been shown to mediate diverse cellular pathways including cell survival, proliferation, differentiation, and cell death in many different cell types (Salmond et al., 2009) . Previous studies using Lck knock-out mice demonstrated that Lck gene deletion abolished the cardioprotective effect of PC in myocardium (Ping et al., 1999 (Ping et al., , 2002 . Although, Lck is expressed in the brain (Omri et al., 1996; Salter and Kalia, 2004) , its role in neuroprotection and PC has not been previously investigated.
We investigated the role of Lck in PC in the brain using in vitro and in vivo ischemia models and show that Lck is a critical mediator of PC in brain. Furthermore, we show that Lck-associated PC is mediated through its interaction with PKC and activation of another Src kinase, Fyn. In this study, we provide new insights into the mechanisms underlying endogenous neuroprotection, and suggest a novel therapeutic candidate pathway for stroke prevention or treatment.
Materials and Methods
Materials. Cell culture media and reagents (Neurobasal A, B27, glutamine, and penicillin/streptomycin), Lipofectamine 2000, Dynabeads Protein G Immunoprecipitation kit, mouse anti-p59Fyn Ab, and rabbit anti-Src [pY 418 ] Ab were obtained from Invitrogen. Poly-D-lysine, NMDA, 4Ј,6-diamidino-2-phenylindole (DAPI), and propidium iodide (PI) were purchased from Sigma. Lactate dehydrogenase (LDH) assay kit (CytoTox 96 Non-Radioactive cytotoxicity assay) and ProFluor Srcfamily kinase assay kit were obtained from Promega. BCA Protein assay reagents, SuperSignal West Pico Chemiluminescent Substrate, RIPA cell lysis buffer, Halt protease and phosphatase inhibitor mixture, and OnTarget plus SMARTpool siRNA against mouse Lck, Fyn, or Yes and its nontargeting negative control siRNA were purchased from Thermo Fisher Scientific. RNeasy Mini kit was obtained from Qiagen, and BioPORTER reagent was from Genlantis. Mouse anti-protein kinase C (PKC) Ab and mouse anti-p56Lck Ab were from BD Biosciences. Mouse anti-␤-actin Ab, rabbit anti-Yes Ab, and mouse anti-glyderaldehyde-3-phosphate dehydrogenase (GAPDH) Ab were purchased from Abcam, Cell Signaling Technology, and Millipore, respectively. All other reagents were used with highest purity available.
Primary cortical neuronal cultures. All animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at Michigan State University. Primary cortical neuronal cultures were established as previously described (Yim et al., 2010) . Briefly, cerebral cortices were isolated from C57BL/6 newborn mice at postnatal day 0 and dissociated in dissection media (81.8 mM Na 2 SO 4 , 30 mM K 2 SO 4 , 5.8 mM MgCl 2 , 0.252 mM CaCl 2 , 1.5 mM HEPES, 20 mM glucose, and 0.001% phenol red, pH 7.6) supplemented with 4 mM L-cysteine, 10 U/ml papain (Worthington), and 1000 U/ml DNase (Roche) for 30 min at 37°C. After dissociation, cells were washed with Neurobasal A and then triturated with pipette. Cells (1 ϫ 10 6 ) were plated onto poly-D-lysine-precoated 12 well plates. Three days after plating, 50% of the medium was changed, and subsequently replaced every 3 d. Neuronal cultures were maintained in CO 2 incubator (5% CO 2 / 95% air balance) at 37°C, and used between days in vitro (DIV) 7 and 11.
Determination of NMDA-induced cytotoxicity. Delayed NMDAinduced cytotoxicity was measured at 24 h after NMDA exposure using PI-staining or LDH assay as previously described (Tauskela et al., 2003; Wetzel et al., 2008) . On DIV 9, cultured neurons were exposed to NMDA for 20 min and maintained in CO 2 incubator for 24 h. Cells were stained with 5 g/ml PI at 37°C for 30 min, and examined by fluorescent microscopy (Nikon) or fluorescent microplate reader (Ascent, Thermo Lab Systems). The extent of LDH leakage was measured in conditioned media using a Cytotox 96 Non-Radioactive cytotoxicity assay. The cell viability in sister cells treated with 100 M NMDA was used as the total cell death (100%).
In experiments with NMDA-induced PC, cells were exposed to sublethal dose of NMDA (10 M) for 20 min on DIV 8, and subsequently exposed to lethal dose of NMDA (50 M) at 24 h after PC on DIV 9. Cell viability was measured as described above on DIV 10.
PKC activity modulating peptides. The peptide inhibitor for PKC translocation (EAVSLKPT; V1-2) (Chen et al., 2005) and PKC selective agonist (HDAPIGYD; RACK) (Inagaki et al., 2005) were synthesized by Macromolecular Structure Facility (Department of Biochemistry, Michigan State University). V1-2 or RACK was diluted and mixed with BioPORTER reagent (Alano et al., 2010) . Cells were incubated with BioPORTER-peptide complex for 4 h at 37°C. After transfection, cell were washed with complete culture media and immediately exposed to NMDA. Cell transfection efficiency was confirmed using parallel transfections with fluorescein-labeled control IgG, as suggested by the manufacturer.
Gene silencing with siRNAs. Primary cortical neurons were transfected with 10 nM siRNAs using Lipofectamine 2000 transfection reagent (Ueda et al., 2007) . On DIV 5, neurons were incubated with Neurobasal A containing Lipofectamine 2000 (0.2%) and 10 nM siRNAs against mouse Lck, Yes, or Fyn, or nontargeting negative control for 4 h at 37°C. After transfection, the original medium collected before transfection was replaced. To ensure gene silencing efficiency, target mRNA or protein samples were collected after 48 and 96 h after siRNA transfection, and measured by quantitative real time PCR or Western blot, respectively.
Immunoprecipitation. Neuronal lysates were applied to immunoprecipitation using magnetic beads (Dynabeads, Invitrogen) (Gudz et al., 2006) . Cell lysates were harvested using RIPA buffer, and centrifuged at 14,000 ϫ g for 15 min. Protein concentrations were determined by BCA assay, and then adjusted to 1 mg/ml. Five hundred microliters of lysates were applied to immunoprecipitation using specific anti-Lck or Fyn Abconjugated magnetic beads (Dynabeads, Invitrogen). Eluted immunoprecipitates were used for kinase assay or Western blot.
Lck/Fyn kinase activity. After immunoprecipitation with anti-Lck or Fyn Ab, eluted immunoprecipitates were analyzed using a ProFluor SrcFamily Kinase Assay (Watanabe et al., 2010) . The total kinase amounts in immunoprecipitates were examined by Western blot, and the kinase activity from the corresponding control was defined as one-fold.
Western blot. After the cell lysate was collected using RIPA buffer supplemented with Halt protease/phosphatase inhibitor mixture, the protein concentrations were determined using BCA assay. The protein samples (20 g/lane) were separated in 12% Tris-HCl SDSpolyacrylamide Ready Gels (Bio-Rad) and were transferred to PVDF membrane (Millipore). After blocking with 5% BSA, membranes were incubated overnight at 4°C with primary antibodies of anti-Lck (1:1000), anti-Fyn (1:500), anti-p-Src/Fyn (1:1000), anti-PKC (1:1000), anti-Yes (1:1000), anti-GAPDH (1:5000), or anti-␤-actin (1:5000). Horseradish peroxidase-conjugated secondary antibodies (1:5000, Cell Signaling Technology) were used as secondary antibodies. The immune complexes were visualized by enhanced chemiluminescence using SuperSignal West Pico Chemiluminescent Substrate. Bands were quantified by NIH ImageJ program, and normalized by the corresponding loading controls of ␤-actin or GAPDH. All immunoblots were repeated for at least three independent experiments.
Quantitative real time PCR. Total RNA was extracted using RNeasy mini kit (Qiagen), and converted into cDNA using TaqMan reverse transcription kit (Applied Biosystems) for quantitative real-time PCR (qRT-PCR). The specific primer sequences were as follows: 18S, forward: ACC GCA GCT AGG AAT AAT GGA; reverse: GCC TCA GTT CCG AAA ACC A; Lck, forward: TGG AGA ACA TTG ACG TGT GTG; reverse: ATC CCT CAT AGG TGA CCA GTG; and Fyn, forward: ACC TCC ATC CCG AAC TAC AAC; reverse: CGC CAC AAA CAG TGT CAC TC. Quantification of gene copies was performed on the 7500 Real-Time PCR system, using SYBR Green master mix (Applied Biosystems). PCR cycles consisted of three stages with an initial step at 95°C for 10 min followed by 40 cycles at 95°C for 15 s and 60°C for 1 min, and a final stage for dissociation curve. Relative mRNA expressions were calculated by the comparative C T method (2 Ϫ⌬⌬Ct ), and normalized to the endogenous 18S control.
Oxygen glucose deprivation. Oxygen glucose deprivation (OGD) on primary cortical neurons was performed as previously described (Plesnila et al., 2001; Wetzel et al., 2008) . On DIV 9, cells were washed, and the medium was replaced by glucose free Earl's balanced salt solution (5.4 mM KCl, 26.2 mM NaHCO 3 , 116 mM NaCl, 1 mM NaH 2 PO 4 , 0.8 mM MgSO 4 , 1.8 mM CaCl 2 , and 0.01 mM glycine, pH 7.4). Cell plates were placed in a closed chamber (Billups-Rothenberg) filled with 5% CO 2 / 95% N 2 for 2 h at 37°C. OGD was terminated by returning the cultures to normal condition of complete Neurobasal A media and 5%CO 2 / 95% air. After 24 h, OGD-induced cell death was examined by PI staining and LDH assay as described above. To induce OGD-PC, cells were exposed to sublethal OGD for 30 min on DIV 8, and lysed for Western blot/kinase assay or further exposed to lethal OGD for 2 h on DIV 9 for cytotoxicity assay.
Permanent middle cerebral artery occlusion. All animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of the Michigan State University. Focal ischemia was induced by permanent middle cerebral artery occlusion (pMCAO) in male C57BL/6 mice (22-27 g; Charles River Laboratory) as previously described (Rajanikant et al., 2007) . Mice were kept under isoflurane anesthesia during the entire procedure and their body temperature was maintained at 37°C. A skinincision was made to create a small subtemporal craniotomy to expose the middle cerebral artery, and the artery was occluded using a bipolar coagulator. To ensure the completeness of the occlusion, the cerebral blood flow in the MCA territory was measured before and after MCAO by a laser doppler (Perimed PF-3). After incision closure, the animals were allowed to recover from the anesthesia. At 24 h after pMCAO, animals were killed, and then the brains were removed and sliced into 1 mm coronal sections, and stained with 2,3,5-triphenyl tetrazolium chlo- ride (TTC) solution (Ruscher et al., 2011) . The infarct area was measured using the NIH ImageJ program from the scanned images of stained brain slices. The infarct volume in each slice was calculated by taking the average of the infarct areas on both sides of the slice and multiplying it by the section thickness.
In vivo preconditioning. PC was induced 48 h before pMCAO by exposing the animals for 2 h to a continuously flushed gas mixture of 8% oxygen/92% nitrogen at a rate of 1.5 L/min. Control animals were exposed to ambient air. After 2 h, the mice were returned to normal atmospheric conditions. At 48 h after PC, the mice were subjected to pMCAO and the differences in infarct volumes between the groups were determined at 24 h after pMCAO by TTC staining as described above. To determine the effect of A420983 on PC protection against brain infarction, mice were orally administered with vehicle or 18 mg/kg A420983 immediately after PC and every 12 h thereafter for 48 h before pMCAO.
Statistics. We calculated the means and SEM for all treatment groups. The data were subjected to Student's t test to determine the significant differences between treatment groups. Statistical analysis was performed using SPSS software. In all cases, a p value of Ͻ0.05 was considered significant.
Results

Lck mediates preconditioning in NMDA-induced neuronal death
Only cultures which were Ͼ90% positive for neuronal specific markers were used. NMDA-induced delayed cytotoxicity in primary cortical neurons has been used as an in vitro model of ischemic neuronal cell death (Manzerra et al., 2001; Tauskela et al., 2003; Lin et al., 2008) . NMDA-induced (10 -100 M) cytotoxicity was observed in a dose-dependent manner. Confirming previous reports, cells that were preconditioned by preexposure to sublethal NMDA (10 M) exhibited decreased vulnerability to subsequent exposure to lethal concentrations of NMDA (50 M) (Fig. 1 A, B) .
We then examined the effect of decreasing Lck protein on PC using siRNA against Lck and mutant mice deficient for the Lck gene. Lck gene silencing using siRNA abolished PC (Fig. 1C,D) , suggesting that Lck plays a critical role in neuronal PC. Silencing efficiency was confirmed by demonstrating both decreased Lck protein and mRNA levels ( Fig. 1 E, F ) . Similarly, although cortical neurons isolated from Lck Ϫ/Ϫ mice exhibited a cytotoxic response to NMDA in a similar fashion to wild-type neurons, neurons from Lck Ϫ/Ϫ mice could not be preconditioned (Fig. 1G) . Significantly, silencing another Src kinase, Yes, by using siRNA against Yes did not affect PC (Fig. 1C, D, H ) , suggesting that not all Src family members mediate PC.
To determine whether changes in Lck kinase activity mediate PC, neuronal lysates were immunoprecipitated with Lck antibody. The total Lck amount in each immunoprecipitate was not different (Fig.  1 I, top) , but Lck kinase activity was significantly increased by NMDA PC (Fig. 1 I) . Neither the total Lck protein levels nor the mRNA levels were affected by NMDA PC (Fig. 1 J, K ) , suggesting that enhanced Lck activity rather than enhanced enzyme levels mediate PC.
Lck mediates PC in the OGD model of PC
To confirm our findings in another in vitro model of PC, we used OGD, a well established in vitro model, for ischemic neuronal damage and PC (Stenzel-Poore et al., 2004; Wetzel et al., 2008) . Neuronal cells were preconditioned with exposure to 30 min OGD. Confirming previous reports, preconditioned neurons exhibited decreased vulnerability to subsequent lethal exposure to 2 h OGD (Fig. 2 A) . Silencing Lck using siRNA abolished OGD PC protection (Fig. 2 B) , and similarly, neurons from Lck Ϫ/Ϫ mice, mutant mice deficient for the Lck gene, could not be preconditioned by OGD (Fig. 2C) . Lck kinase activation but not mRNA or protein levels (Fig. 2 D) was increased after OGD PC in a similar pattern to NMDA PC. Together, these findings suggest that Lck mediates PC regardless of type of the preconditioning stimuli.
Lck mediates PC in focal cerebral ischemia
Next, we sought to determine the role of Lck in PC in vivo using the mouse pMCAO model. PC (exposure to 8% oxygen for 2 h) of mice followed by pMCAO at 48 h after PC significantly reduced the infarct volume compared with the control group, as measured by TTC staining at 24 h after MCAO (Fig.  3A) . To determine whether Lck influences in vivo PC neuro- protection, we used Lck Ϫ/Ϫ mice and an orally active Lck antagonist, A420983 (Waegell et al., 2002) . First, we examined whether the vulnerability to pM-CAO is affected by Lck gene deletion (Fig. 3B) (Fig. 3C) . Physiological parameters during surgical procedure were not different between the groups as shown in Table 1 . Similarly, mice treated with A420983 did not exhibit decreased infarct volumes after PC compared with vehicle treated mice (Fig. 3D) .
Protein kinase C regulates Lck activation in PC neuroprotection
Previous data suggest that Lck mediates cardioprotection through the formation of PKC-Lck signaling module (Ping et al., 1999 (Ping et al., , 2002 . To investigate the upstream regulators of Lck in PC in the brain, we investigated the involvement of PKC in the NMDA PC model. Pretreatment with a PKC inhibitor (V1-2;10 M) abolished PC, suggesting that PC is mediated by PKC activation (Fig. 4 A, B) . Moreover, pharmacological activation of PKC by RACK (10 M) simulated NMDA PC, resulting in decreased vulnerability to lethal NMDA toxicity in cortical neuronal cells (Fig. 4 A, B) .
Next, we sought to determine whether interaction between PKC and Lck occurs in preconditioned neurons using coimmunoprecipitation (Ping et al., 2002) . PKC was found to coreside in Lckimmunoprecipitates, and this interaction was significantly increased after NMDA PC (Fig. 4C) . After inhibiting PKC by V1-2, NMDA-induced Lck kinase activation during PC was abolished (Fig. 4 D) , suggesting that Lck activity is regulated by PKC activation during PC.
Fyn is the downstream target of Lck
Published data suggest that Lck can regulate Fyn, another member of the Src family kinases (Suzuki and Okumura-Noji, 1995; Filipp et al., 2008; Isosaka et al., 2008) . To determine whether Fyn is the downstream target of Lck in PC, we first examined Fyn phosphorylation and activity in NMDA PC. Immunoblotting to Fyn phosphorylated at Tyr 417, a positive regulatory residue for its activation (Filipp et al., 2008) , revealed that p-Fyn levels are significantly enhanced during NMDA PC (Fig. 5A) . Similarly, Fyn kinase activity from Fyn-immunoprecipitates was increased by NMDA PC (Fig. 5B) , suggesting that Fyn is activated during PC. While inhibition of Fyn by silencing Fyn (siFyn) transfection did not affect NMDA-induced cytotoxicity (Fig. 5C ), siFyn significantly abolished PC (Fig. 5D) , reflecting that Fyn activation is critical for PC. Silencing efficiency was determined (Fig. 5E) . We also investigated the role of Fyn in PC using OGD ischemia model, and found similar effects to NMDA PC (Fig. 5 F, G) .
Next we examined changes in p-Fyn levels after silencing Lck using siRNA or in neurons from Lck Ϫ/Ϫ mice. NMDA PCinduced Fyn phosphorylation was not increased after Lck gene silencing with siRNA or in neurons from Lck Ϫ/Ϫ mice (Fig.  5 H, I ), implying that Lck is the upstream regulator of Fyn activation. While Fyn is regulated by Lck, siFyn did not affect PC- A, In vivo PC was performed by exposing mice to 8% O 2 /92% N 2 for 2 h. At 48 h after PC, the middle cerebral artery was permanently occluded for the induction of focal ischemia. Brain damage was determined by the infarct volumes at 24 h after ischemia using 2,3,5-triphenyl tetrazolium chloride staining. The representative brain slides are shown. B, Vulnerability to pMCAO was compared among wild-type (WT), Lck ϩ/Ϫ , and Lck Ϫ/Ϫ mice and no significant difference was found. C, Protective effect of in vivo hypoxic PC against ischemic brain damage was not observed in Lck Ϫ/Ϫ mice. D, Lck antagonism by A420983, an orally active Lck antagonist, reversed in vivo PC neuroprotection. A420983 (18 mg/kg) was orally administered to mice immediately after PC and every 12 h thereafter for 48 h before focal ischemia. Anta, Lck antagonist A420983. **p Ͻ 0.01 versus control without PC; # p Ͻ 0.05 versus PC. A, n ϭ 10 -11; B, n ϭ 11-15; C, n ϭ 8 -9; D, n ϭ 14 -16. All values are means Ϯ SEM and analyzed by Student's t test. induced Lck kinase activation (Fig. 5J ) , confirming that Fyn is the downstream target of Lck. Notably, V1-2 reversed PC-induced Fyn phosphorylation (Fig. 5K ) , suggesting that the PKC-LckFyn axis is critical in PC.
Discussion
Our data provide new insights into the role of Lck in PC in the brain. Using in vitro models of PC, we showed that enhanced Lck kinase activity mediates PC. Neurons derived from Lck Ϫ/Ϫ mice or neurons in which the Lck gene was silenced by siRNA could not be preconditioned. We also showed that PKC, a kinase that has been shown to be an important mediator of PC, is an upstream activator of Lck. Significantly, we have identified Fyn as a downstream target for Lck. Lck activation during PC leads to the activation of Fyn and silencing Fyn abolished PC. The important role of Lck was verified in vivo using an animal model of stroke. Lck gene deletion or pharmacological Lck antagonism blocked PC in vivo. Together, our data show that the PKC-Lck-Fyn signaling axis is an important mediator of PC. We cannot, however, exclude the possibility that Lck and/or Fyn could be activated by other yet-to be-identified upstream signals.
We used sublethal NMDA, OGD, and hypoxia to induce tolerance, but other models also exist (McLaughlin et al., 2003; Hoyte et al., 2006; Dave et al., 2008; Hu et al., 2010) . Whether Lck plays a role in those preconditioning paradigms is not known. Although we used highly purified neuronal cultures, the potential influence of small amounts of other non-neuronal cells such as astrocytes and microglia cannot be entirely discounted and need further investigation. For the in vivo studies, we determined 24 h outcomes (infarct volume). Long-term outcomes (both histological and behavioral) remain to be determined in future studies.
Future studies will also need to explore the relative contribution of Lck and Fyn at various time intervals after PC, because rapid tolerance and delayed tolerance may be mechanistically distinct (Bright et al., 2008; Obrenovitch, 2008) .
The role of PKC in PC
Previous studies showed that PKC is an important mediator of PC in both heart and brain (Raval et al., 2003; Chou and Messing, 2005; Jia et al., 2007; Bright et al., 2008; DeFazio et al., 2009) . PKC is activated by a number of preconditioning stimuli, including hypoxia and transient ischemia. Downstream targets of PKC are many and include GABA signaling, mitochondrial function alteration, and extracellular signal-regulated kinases (ERKs) (Jia et al., 2007; Dave et al., 2008; DeFazio et al., 2009 ). However, the precise molecular targets of PKC still remain unclear. It is unlikely that PC involves a single obligatory mediator, and it is likely that there is activation of a constellation of different pathways that ultimately leads to tolerance (Brooks and Hearse, 1996) . It is possible that other mediators and pathways may play a greater role depending on the PC stimulus. Studying other PC models will be important to better understand this complicated endogenous neuroprotective mechanism.
Lck-a novel mediator of PC in brain
Lck has been primarily investigated in the immune system in T lymphocytes. Lck plays an essential role in T cell receptor (TCR) signaling, modulating T cell activation and differentiation (Palacios and Weiss, 2004; Salmond et al., 2009) . Recent data also suggest that Lck plays a role in mitochondrial signaling in apoptosis (Samraj et al., 2006; Kim et al., 2008) . Until now, most studies have focused on the selective inhibition of Lck for therapeutic immunosuppression and treatment of immunological diseases, such as rheumatoid arthritis, based on its role in the immune system (Benati and Baldari, 2008; Meyn and Smithgall, 2008) . Our data show that Lck activation contributes to PC and that inhibition of Lck abolishes PC. Whether activation of Lck would induce neuroprotection is not known and selective Lck activators are not available at this time. Although recent data suggest that Unc 119 can activate Lck in T cells (Gorska et al., 2004) , it can also activate other Src kinases that would make it difficult to tease out the precise role of Lck activation. Another strategy worthy of further investigation may involve using PKC activators to activate Lck.
Lck can also modulate the activity of other Src family kinase members such as Fyn, by phosphorylation of its active site Tyr 417 (Filipp et al., 2003) . Previous studies suggest that Lck and Fyn have overlapping cellular functions and are closely related to each other (Filipp et al., 2003 (Filipp et al., , 2008 . However, this has not been previously examined in PC or in the brain. Our data show that neurons from Lck Ϫ/Ϫ mice or wild-type neurons transfected with siRNA against Lck (siLck) exhibited significantly reduced Fyn 
Downstream targets of Fyn
The precise function of Fyn in the brain is not known. Fyn regulates NMDA receptors by the phosphorylation of its subunits (Salter and Kalia, 2004; Wu et al., 2007) , which modulate NMDA receptor channel activity (Takasu et al., 2002) . Following transient ischemia in rats, phosphorylation of the NR2A and, to a lesser extent, NR2B subunits of the NMDA receptor is increased (Takagi et al., 1999) . The association between Fyn and NR2A following ischemia is accompanied by increased NR2A phosphorylation (Hou et al., 2003; Jiang et al., 2008) . Ischemia also enhances the association between Fyn and other proteins in the NMDA receptor complex, such as PSD-95 and the L-type voltage gated calcium channel (Hou et al., 2003) . Administration of a selective NR2A antagonist increased neuronal death and abolished preconditioning, whereas administration of an NR2B antagonist decreased neuronal death and enhanced the preconditioning effect . Fyn has been implicated in the phosphorylation and activation of both of these subunits, therefore it is possible that Fyn activity modulates preconditioning by influencing NR2A and NR2B activity. Another potential downstream candidate target is carveolin, a scaffolding protein that may also influence the activation of NMDA receptors (Head et al., 2008) . Although our laser Doppler studies did not show any differences in blood flow between experimental groups in the in vivo studies, we cannot, however, discount the possibility that changes in blood flow may have occurred in the penumbra of the infarct. The precise downstream pathways that are modulated by Fyn activation are not known and need further investigation.
Other Src family members
Although the role of Src family kinases in neurons has been investigated in previous studies, the individual importance of each family member is not fully understood due to the lack of selective inhibitors/activators. Conventional inhibitors such as PP1 and PP2 lack selectivity (Hanke et al., 1996) . To overcome this, we used RNA silencing to inhibit specific Src family members, Lck, Fyn, and Yes. We demonstrated that Lck and Fyn, but not Yes, are involved in PC. It is possible that other Src kinases may also be involved in PC and their function may not be mutually exclusive. An important point for consideration when manipulating Src kinases is that they may enhance angiogenesis that may facilitate recovery after stroke (Schlessinger, 2000; Slevin et al., 2006) .
Implications
A desperate need exists for new stroke therapies (Fagan, 2010) . Although PC is a powerful endogenous neuroprotective mechanism, translation of preclinical findings into therapies still remains a challenge . Our data suggest that selective activation of Lck or Fyn may represent a novel therapeutic strategy for stroke therapy development.
